Biomarker Research · Nov 19, 2026
Cell-free DNA-guided detection, surveillance, and therapeutic adaptation for breast cancer
By Li C, Chow TW, Tey SK et al.
Plasma cell-free DNA (cfDNA) analysis provides a minimally invasive approach to breast cancer assessment across early detection, minimal residual disease (MRD) monitoring, and treatment adaptation in advanced disease. This review evaluates these applications by distinguishing analytical validity, clinical detection performance, prognostic validity, and clinical utility. In early detection, assays integrating genomic, epigenomic, fragmentomic, and protein-based features have shown encouraging performance in evaluated cohorts; however, sensitivity remains limited in low-burden disease, particularly stage I breast cancer. Their potential clinical role depends on the incremental information they provide beyond established imaging and diagnostic pathways. In the curative-intent setting, circulating tumor DNA detection after treatment is associated with recurrence risk and can precede clinical or radiographic relapse, supporting prognostic stratification and the design of MRD-guided intervention trials. Whether such interventions improve clinical outcomes remains a central unresolved question. In advanced breast cancer, plasma genotyping supports treatment selection in defined molecular contexts. Randomized trials of ESR1 mutation-guided endocrine switching have demonstrated progression-free survival benefits with specific treatment strategies, providing evidence beyond biomarker-outcome associations, although overall survival benefit remains to be established. Across applications, interpretation depends on assay characteristics, molecular input, disease setting, sampling schedule, and the clinical decision being evaluated. Future studies should connect assay performance to patient benefit through comparison with existing care, clinically meaningful endpoints, and assessment of treatment burden and downstream investigations. This approach will help define where cfDNA testing can contribute meaningfully to breast cancer management.
doi.org/10.1186/s40364-026-01048-1Open accessPubMed 43058824Biomarkers